Psychedelics

The Trump administration has fast-tracked research into psychedelics, and experts suggest it may lead to their use in treating children in the near future.

President Trump is attempting to accelerate research into psychedelics as potential treatments for mental healthcare, which could lead to new opportunities and risks.

The Trump administration has signaled a shift in Republican drug policy by fast-tracking psychedelic drug reviews and rescheduling medical marijuana, diverging from past stances like Nixon's 'war on drugs.' This marks a departure from the GOP's traditional 'just say no' approach to drug regulation.

The US has issued an executive order to accelerate research on mind-altering drugs, including ibogaine, a psychedelic substance. While some researchers welcome the move, others caution that careful oversight is necessary to ensure safety and efficacy.

FDA Commissioner Michael Makary commented on President Trump's executive order aimed at increasing access to psychedelics. The EO seeks to streamline regulatory pathways for psychedelic therapies, potentially accelerating their availability for medical use.

President Trump signed an executive order to advance research on psychedelics for mental illness treatment. This follows his 2025 reclassification of marijuana as a less dangerous drug. Josh Kesselman, founder of RAW rolling papers and publisher of High Times Magazine, is among those supporting the move.

President Trump signed an order to accelerate the review of psychedelics for treating mental health disorders, specifically endorsing psilocybin and ibogaine. The order aims to expedite research and regulatory processes for these substances.

President Trump, joined by Joe Rogan, signed an executive order directing the federal government to expedite the review and relax restrictions on psychedelics, including ibogaine, for potential therapeutic applications. The order aims to accelerate the development of psychedelic-based treatments by reducing regulatory barriers.

President Trump signed an executive order to ease U.S. restrictions on psychedelic research, including ibogaine, a drug used in some countries to treat post-traumatic stress disorder.

President Donald Trump signed an executive order directing the FDA to expedite the review of psychedelics designated as breakthrough therapy drugs. The order aims to accelerate access to experimental treatments for severe mental illness and depression, particularly for veterans.

President Donald Trump signed an executive order directing the FDA to expedite reviews of psychedelics designated as breakthrough therapy drugs, aiming to accelerate access to treatments for severe mental illness and depression. The order emphasizes these therapies' potential to help veterans and patients in advanced clinical trials.

AI chatbots disseminated information about a fabricated disease 'bixonimania' following the release of two fake preprints by scientists. The article also discusses similarities among psychedelics and a revised report on climate change's economic costs.